Showing results (91-100 of 135) with videos related to
Sort By:
Pageof 14
Head & Neck|October 2, 2019
Probe-based fluorescence dosimetry of an antibody-dye conjugate to identify head and neck cancer as a first step to fluorescence-guided tissue preselection for pathological assessmentNaoki Nishio, Stan van Keulen, Nynke S van den Berg, et al.Cancer|June 28, 2019
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trialRobert Haddad, Fernando Concha-Benavente, George Blumenschein, et al.Melanoma Research|June 7, 2012
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanomaKevin B Kim, Victor Prieto, Richard W Joseph, et al.International Journal of Radiation Oncology, Biology, Physics|March 3, 2012
Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumorsNicholas Trakul, Christine N Chang, Jeremy Harris, et al.The Journal of Clinical Investigation|November 12, 2019
Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistanceDhanya K Nambiar, Todd Aguilera, Hongbin Cao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2019
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab UseRobert L Ferris, Lisa Licitra, Jerome Fayette, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research GroupShanthi Marur, Shuli Li, Anthony J Cmelak, et al.JAMA Network Open|June 2, 2023
Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled TrialNancy Y Lee, Jonathan Harris, John Kim, et al.The Oncologist|May 31, 2022
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141Maura L Gillison, George Blumenschein, Jerome Fayette, et al.Cancer Chemotherapy and Pharmacology|February 22, 2012
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignanciesPrithviraj Bose, Edward B Perkins, Connie Honeycut, et al.Pageof 14